Self-assembled amphotericin B-loaded polyglutamic acid nanoparticles: Preparation, characterization and in vitro potential against Candida albicans

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 1609-1623

  Zia, Qamar ^a   Khan, Aijaz Ahmed ^a   Swaleha, Zubair ^a   Owais, Mohammad ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

Amphotericin B; Candidiasis; Polyglutamic acid; Toxicity

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; NANOPARTICLE; POLYGLUTAMIC ACID NANOPARTICLE; UNCLASSIFIED DRUG; ANTIFUNGAL AGENT; POLYGLUTAMIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; BIOFILM; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDIASIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; FEMALE; HISTOPATHOLOGY; IN VITRO STUDY; MAMMAL CELL; MOUSE; MTT ASSAY; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; SPECTROMETRY; TOXICITY TESTING; ZETA POTENTIAL; ANIMAL; CELL LINE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS;

CANDIDA ALBICANS; MAMMALIA;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CELL LINE; CELL SURVIVAL; MICE; NANOPARTICLES; POLYGLUTAMIC ACID;

EID: 84924301569     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S63155     Document Type: Article

References (103)

1. Barratt G, Bretagne S. Optimizing efficacy of amphotericin B through nanomodification. Int J Nanomedicine. 2007;2:301–313.
2. Torrado JJ, Espada R, Ballesteros MP, Torrado-Santiago S. Amphotericin B formulations and drug targeting. J Pharm Sci. 2008; 97:2405–2425.
3. Kleinberg M. What is the current and future status of conventional amphotericin B? Int J Antimicrob Agents. 2006;27(S1):12–16.
4. Ha YE, Peck KR, Joo EJ, et al. Impact of first-line antifungal agents on the outcomes and costs of candidemia. Antimicrob Agents Chemother. 2012;56:3950–3956.
5. Laniado-Laborin R, Cabrales-Vargas MN. Amphotericin B: side effects and toxicity. Rev Iberoam Micol. 2009;26:223–227.
6. Gupta S, Pal A, Vyas SP. Drug delivery strategies for therapy of visceral leishmaniasis. Expert Opin Drug Deliv. 2010;7:371–402.
7. Deray G. Amphotericin B nephrotoxicity. J Antimicrob Chemother. 2002;49(S1):37–41.
8. Sabra R, Branch RA. Amphotericin B nephrotoxicity. Drug Saf. 1990;5:94–108.
9. Dupont B. Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother. 2002;49(S1):31–36.
10. Herbrecht R, Natarajan-Ame S, Nivoix Y, Letscher-Bru V. The lipid formulations of amphotericin B. Expert Opin Pharmacother. 2003;4: 1277–1287.
11. Antoniadou A, Dupont B. Lipid formulations of amphotericin B: where are we today? J Med Mycol. 2005;15:230–238.
12. Adler-Moore PJ, Proffitt TR. Development, characterization, efficacy and mode of action of Ambisome, a unilamellar liposomal formulation of Amphotericin B. J Liposome Res. 1993;3:429–450.
13. Adler-Moore J, Proffitt RT. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J Antimicrob Chemother. 2002;49:21–30.
14. Bruynesteyn K, Gant V, McKenzie C, et al. A cost-effectiveness analysis of caspofungin vs liposomal amphotericin B for treatment of suspected fungal infections in the UK. Eur J Haematol. 2007;78:532–539.
15. Olliaro P, Darley S, Laxminarayan R, Sundar S. Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India. Trop Med Int Health. 2009;14:918–925.
16. Adler-Moore JP, Proffitt RT. Amphotericin B lipid preparations: what are the differences? Clin Microbiol Infect. 2008;14(S4):25–36.
17. Olson JA, Adler-Moore JP, Jensen GM, et al. Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products. Antimicrob Agents Chemother. 2008;52:259–268.
18. Cifani, C., Costantino, S., Massi, M., Berrino, L. Commercially available lipid formulations of amphotericin B: Are they bioequivalent and therapeutically equivalent?, Acta Biomedica, Volume 83, Issue 2, 2012, Pages 154-163.
19. Patel GP, Crank CW, Leikin JB. An evaluation of hepatotoxicity and nephrotoxicity of liposomal amphotericin B (L-AMB). J Med Toxicol. 2011;7:12–15.
20. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2010;75:1–18.
21. Saffie-Siebert R, Ogden J, Parry-Billings M. Nanotechnology approaches to solving the problems of poorly water-soluble drugs. Drug Discovery World. 2005;3:71–76.
22. Yang D, Yu L, Van S. Clinically relevant anticancer polymer paclitaxel therapeutics. Cancers (Basel). 2011;3:17–42.
23. Kopecek J, Kopecková P, Minko T, Lu ZR, Peterson CM. Water soluble polymers in tumor targeted delivery. J Control Release. 2001; 74:147–158.
24. Farazuddin M, Sharma B, Khan AA, Joshi B, Owais M. Anticancer efficacy of perillyl alcohol-bearing PLGA microparticles. Int J Nanomedicine. 2012;7:35–47.
25. Farazuddin M, Chauhan A, Khan RM, Owais M. Amoxicillin-bearing microparticles: potential in the treatment of Listeria monocytogenes infection in Swiss albino mice. Biosci Rep. 2011;31:265–272.
26. Wang C, Feng M, Deng J, et al. Poly(alpha-glutamic acid) combined with polycation as serum-resistant carriers for gene delivery. Int J Pharm. 2010;398:237–245.
27. Li C. Poly(L-glutamic acid)-anticancer drug conjugates. Adv Drug Deliv Rev. 2002;54:695–713.
28. Li C, Wallace S. Polymer-drug conjugates: recent development in clinical oncology. Adv Drug Deliv Rev. 2008;60:886–898.
29. Paz-Ares L, Ross H, O’Brien M, et al. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br J Cancer. 2008;98:1608–1613.
30. Sabbatini P, Aghajanian C, Dizon D, et al. Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. J Clin Oncol. 2004;22:4523–4531.
31. Cho CS, Kobayashi A, Takei R, et al. Receptor-mediated cell modulator delivery to hepatocyte using nanoparticles coated with carbohydrate-carrying polymers. Biomaterials. 2001;22:45–51.
32. Nilsson-Ehle I, Yoshikawa TT, Edwards JE, Schotz MC, Guze LB. Quantitation of amphotericin B with use of high-pressure liquid chromatography. J Infect Dis. 1977;135:414–422.
33. Barwicz J, Christian S, Gruda I. Effects of the aggregation state of amphotericin B in its toxicity to mice. Antimicrob Agents Chemother. 1992; 36:2310–2315.
34. Nahar M, Dubey V, Mishra D, Mishra P, Dube A, Jain NK. In vitro evaluation of surface functionalized gelatin nanoparticles for macrophage targeting in the therapy of visceral leishmaniasis. J Drug Target. 2010;18:93–105.
35. Olson JA, Adler-Moore JP, Schwartz J, Jensen GM, Proffitt RT. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model. Antimicrob Agents Chemother. 2006;50:2122–2131.
36. Clinical and Laboratory Standards Institute. M27-A2. Vol 22 No 15. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard method. 2nd ed. (ISBN 1-56238-469-4). Wayne, PA, USA: Clinical and Laboratory Standards Institute; 2002.
37. van Etten EW, van Vianen W, Hak J, Bakker-Woudenberg IA. Activity of liposomal amphotericin B with prolonged circulation in blood versus those of AmBisome and Fungizone against intracellular Candida albicans in murine peritoneal macrophages. Antimicrob Agents Chemother. 1998;42:2437–2439.
38. Bachmann SP, Van de Walle K, Ramage G, et al. In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob Agents Chemother. 2002;46:3591–3596.
39. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother. 2002;46:1773–1780.
40. Vandermeulen G, Rouxhet L, Arien A, Brewster ME, Preat V. Encapsulation of amphotericin B in poly(ethylene glycol)-block-poly(ε-caprolactone-co-trimethylene carbonate) polymeric micelles. Int J Pharm. 2006;309:234–240.
41. Choi KC, Bang JY, Kim PI, Kim C, Song CE. Amphotericin B-incorporated polymeric micelles composed of poly-(d,l-lactide-co-glycolide)/dextran graft copolymer. Int J Pharm. 2008;355:224–230.
42. Adams ML, Andes RD, Kwon SG. Amphotericin B encapsulated in micelles based on poly(ethylene oxide)-block–poly(L-amino acid) derivatives exerts reduced in vitro haemolysis but maintains potent in vivo antifungal activity. Biomacromolecules. 2003;4:750–757.
43. Falamarzian A, Lavasanifar A. Optimization of the hydrophobic domain in poly(ethylene oxide)-poly(varepsilon-caprolactone) based nano-carriers for the solubilization and delivery of amphotericin B. Colloids Surf Biointerfaces. 2010;81:313–320.
44. Yoo BK, Jalil Miah MA, Lee ES, Han K. Reduced renal toxicity of nanoparticular amphotericin B micelles prepared with partially ben-zylated poly-L-aspartic acid. Biol Pharm Bull. 2006;29:1700–1705.
45. Nishi KK, Antony M, Mohanan PV, Anilkumar TV, Loiseau PM, Jayakrishnan A. Amphotericin B-gum arabic conjugates: synthesis, toxicity, bioavailability, and activities against Leishmania and fungi. Pharm Res. 2007;24:971–980.
46. Conover DC, Zahao H, Longley BC, Shum LK, Greenwald BR. Utility of poly(ethylene glycol) conjugation to create prodrugs of amphotericin B. Bioconjug Chem. 2003;14:661–666.
47. Nicoletti S, Seifert K, Gilbert IH. N-(2-hydroxypropyl)-methacrylam-ide-amphotericin B (HPMA-AmB) copolymer conjugates as antileishmanial agents. Int J Antimicrob Agents. 2009;33:441–448.
48. Ehrenfreund-Kleinman T, Azzam T, Falk R, Polacheck I, Golenser J, Domb JA. Synthesis and characterization of novel water soluble amphotericin B-arabinogalactan conjugates. Biomaterials. 2002; 23:1327–1335.
49. Jansook P, Loftsson T. CDs as solubilizers: effects of excipients and competing drugs. Int J Pharm. 2009;379:32–40.
50. Corware KF, Harris DF, Teo IF, et al. Accelerated healing of cutaneous leishmaniasis in non-healing BALB/c mice using water soluble amphotericin B-polymethacrylic acid. Biomaterials. 2011;32:8029–8039.
51. Kajtar M, Vikmon M, Morlin E, Szejtli J. Aggregation of amphotericin B in the presence of gamma-cyclodextrin. Biopolymers. 1989;28:1585–1596.
52. Ohtani Y, Irie T, Uekama K, Fukunaga K, Pitha J. Differential effects of alpha-, beta-and gamma-cyclodextrins on human erythrocytes. Eur J Biochem. 1989;186:17–22.
53. Donaubauer HH, Fuchs H, Langer KH, Bar A. Subchronic intravenous toxicity studies with gamma-cyclodextrin in rats. Regul Toxicol Pharmacol. 1998;27:189–198.
54. Charvalos E, Tzatzarakis MN, Van Bambeke F, et al. Water soluble amphotericin B-polyvinylpyrrolidone complexes with maintained antifungal activity against Candida spp. and Aspergillus spp. and reduced haemolytic and cytotoxic effects. J Antimicrob Chemother. 2006; 57:236–244.
55. Savic R, Azzam T, Eisenberg A, Maysinger D. Assessment of the integrity of poly(caprolactone)-b-poly(ethylene oxide) micelles under biological conditions: a fluorogenic-based approach. Langmuir. 2006; 22:3570–3578.
56. Chen H, Kim S, He W, et al. Fast release of lipophilic agents from circulating PEG-PDLLA micelles revealed by in vivo Forster resonance energy transfer imaging. Langmuir. 2008;24:5213–5217.
57. Akagi T, Kaneko T, Kida T, Akashi M. Multifunctional conjugation of proteins on/into bio-nanoparticles prepared by amphiphilic poly(gamma-glutamic acid). J Biomater Sci Polym Ed. 2006;17:875–892.
58. Lemke A, Kiderlen A, Kayser O, Amphotericin B. Appl Microbiol Biotechnol. 2005;68:151–162.
59. Pimpang P, Choopun S. Monodispersity and stability of gold nanoparticles stabilized by using polyvinyl alcohol. Chiang Mai J Sci. 2011; 38:31–38.
60. Rosenblatt KM, Bunjes H. Poly(vinyl alcohol) as emulsifier stabilizes solid triglyceride drug carrier nanoparticles in the alpha-modification. Mol Pharm. 2009;6:105–120.
61. Prokop A, Kozlov E, Carlesso J, Davidson M. Hydrogel based colloidal polymeric system for protein and drug delivery: physical and chemical characterization permeability control and applications. Advances in Polymer Sciences. 2002;160:119–173.
62. Beck-Broichsitter M, Ruppert C, Schmehl T, et al. Biophysical investigation of pulmonary surfactant surface properties upon contact with polymeric nanoparticles in vitro. Nanomedicine. 2011;7:341–350.
63. Patila S, Sandberg A, Heckert E, Self W, Sea S. Protein adsorption and cellular uptake of cerium oxide nanoparticles as a function of zeta potential. Biomaterials. 2007;28:4600–4607.
64. Puttipipatkhachorn S, Nunthanid J, Yamamotoc K, Peck GE. Drug physical state and drug–polymer interaction on drug release from chitosan matrix films. J Control Release. 2001;75:143–153.
65. Sutherland MD, Thorkildson P, Parks SD, Kozel TR. In vivo fate and distribution of poly-gamma-D-glutamic acid, the capsular antigen from Bacillus anthracis. Infect Immun. 2008;76:899–906.
66. Pelkmans L. Secrets of caveolae-and lipid raft-mediated endocytosis revealed by mammalian viruses. Biochim Biophys Acta. 2005;1746: 295–304.
67. Espada R, Valdespina S, Dea MA, et al. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation. J Antimicrob Chemother. 2008;61:1125–1131.
68. Legrand P, Romero EA, Cohen BE, Bolard J. Effects of aggregation and solvent on the toxicity of amphotericin B to human erythrocytes. Antimicrob Agents Chemother. 1992;36:2518–2522.
69. Sanchez-Brunete JA, Dea MA, Rama A, et al. Amphotericin B molecular organization as an essential factor to improve activity/toxicity ratio in the treatment of visceral leishmaniasis. J Drug Target. 2004; 12:453–460.
70. Mullen AB, Carter KC, Baillie AJ. Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis. Antimicrob Agents Chemother. 1997;41:2089–2092.
71. Lamy-Freund MT, Ferreira VF, Faljoni-Alario A, Schreier S. Effect of aggregation on the kinetics of autoxidation of the polyene antibiotic amphotericin B. J Pharm Sci. 1993;82:162–166.
72. Mazerski J, Borowski E. Molecular dynamics of amphotericin B. II Dimer in water. Biophys Chem. 1996;57:205–217.
73. Gaboriau F, Cheron M, Leroy L, Bolard J. Physico-chemical properties of the heat-induced ‘superaggregates’ of amphotericin B. Biophys Chem. 1997;66:1–12.
74. Egito LC, de Medeiros SR, Medeiros MG, Price JC, Egito ES. Evaluation of the relationship of the molecular aggregation state of amphotericin B in medium to its genotoxic potential. J Pharm Sci. 2004;93:1557–1565.
75. Bolard J, Legrand P, Heitz F, Cybulska B. One-sided action of amphotericin-B on cholesterol-containing membranes is determined by its self-association in the medium. Biochemistry. 1991;30:5707–5715.
76. Hartsel S, Bolard J. Amphotericin B: new life for an old drug. Trends Pharmacol Sci. 1996;17:445–449.
77. Brajtburg J, Bolard J. Carrier effects on biological activity of amphotericin B. Clin Microbiol Rev. 1996;9:512–531.
78. Espada R, Valdespina S, Alfonso C, Rivas G, Ballesteros MP, Torrado JJ. Effect of aggregation state on the toxicity of different amphotericin B preparations. Int J Pharm. 2008;361:64–69.
79. Iman M, Huang Z, Szoka FC, Jaafari MR. Characterization of the colloidal properties, in vitro antifungal activity, antileishmanial activity and toxicity in mice of a di-stigma-steryl hemi-succinoyl-glycerophosphocholine liposome-intercalated amphotericin B. Int J Pharm. 2011;408:163–172.
80. Jee J, McCoy A, Mecozzi S. Encapsulation and release of amphotericin B from an ABC tri-block fluorous copolymer. Pharm Res. 2012;29: 69–82.
81. Diezi T, Bae Y, Kwon GS. Enhanced stability of PEG-block poly (N-hexyl stearate l-aspartamide) micelles in the presence of serum proteins. Mol Pharm. 2010;7:1355–1360.
82. Yang ZL, Li XR, Yang KW, Liu Y. Amphotericin B loaded poly(ethylene glycol)-poly(lactide) micelles: preparation, freeze-drying, and in vitro release. J Biomed Mater Res A. 2008;85:539–546.
83. Jain JP, Kumar N. Development of amphotericin B loaded polymer-somes based on (PEG)(3)-PLA co-polymers: factors affecting size and in vitro evaluation. Eur J Pharm Sci. 2010;40:456–465.
84. Wang CH, Wang WT, Hsiue GH. Development of polyion complex micelles for encapsulating and delivering amphotericin B. Biomaterials. 2009;30:3352–3358.
85. Skrocka-Knopik A, Bielawski J. The mechanism of the haemolytic activity of polyene antibiotics. Cell Mol Biol Lett. 2002;7:31–48.
86. Jensen GM, Skenes CR, Bunch TH, et al. Determination of the relative toxicity of amphotericin B formulations: a red blood cell potassium release assay. Drug Deliv. 1999;6:81–88.
87. Sperry PJ, Cua DJ, Wetzel SA, Adler-Moore JP. Antimicrobial activity of AmBisome and non-liposomal amphotericin B following uptake of Candida glabrata by murine epidermal Langerhans cells. Med Mycol. 1998;36:135–141.
88. Lee JW, Amantea MA, Francis PA, et al. Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits. Antimicrob Agents Chemother. 1994;38:713–718.
89. Van Etten EW, van den Heuvel-de Groot C, Bakker-Woudenberg IA. Efficacies of amphotericin B-desoxycholate (Fungizone), liposomal amphotericin B (AmBisome) and fluconazole in the treatment of systemic candidosis in immunocompetent and leucopenic mice. J Antimicrob Chemother. 1993;32:723–739.
90. Legrand P, Vertut-Do A, Bolard J. Comparative internalization and recycling of different amphotericin B formulations by a macrophage-like cell line. J Antimicrob Chemother. 1996;37:519–533.
91. Al-Dhaheri RS, Douglas LJ. Apoptosis in Candida biofilms exposed to amphotericin B. J Med Microbiol. 2010;59:149–157.
92. Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T, Ghannoum MA. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J Bacteriol. 2001;183:5385–5394.
93. Ramage G, Vandewalle K, Bachmann SP, et al. In vitro pharma-codynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob Agents Chemother. 2002;46:3634–3636.
94. Baillie GS, Douglas LJ. Effect of growth rate on resistance of Candida albicans biofilms to antifungal agents. Antimicrob Agents Chemother. 1998;42:1900–1905.
95. Stoodley P, Sauer K, Davies DG, Costerton JW. Biofilms as complex differentiated communities. Annu Rev Microbiol. 2002;56:187–209.
96. Hoyer LL, Payne TL, Bell M, et al. Relationship between Candida albicans virulence during experimental hematogenously disseminated infection and endothelial cell damage in vitro. Infect Immun. 2004;72: 598–601.
97. Lo HJ, Kohler JR, Di Domenico B, Loebenberg D, Caccia-Puoti A, Fink GR. Nonfilamentous C. albicans mutants are avirulent. Cell. 1997;90: 939–949.
98. Alam M, Zubair S, Mohammad F, et al. Development, characterization and efficacy of niosomal diallyl disulphide in treatment of disseminated murine candidiasis. Nanomedicine. 2013;9:247-256.
99. Nilsson-Ehle I, Yoshikawa TT, Edwards JE, Schotz MC, Guze LB. Quantitation of amphotericin B with use of high-pressure liquid chromatography. J Infect Dis. 1977;135:414-422.
100. Olson JA, Adler-Moore JP, Schwartz J, Jensen GM, Proffitt RT. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model. Antimicrob Agents Chemother. 2006;50:2122-2131.
101. Clinical and Laboratory Standards Institute. M27-A2. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard-method. 2nd ed. Wayne, PA, USA: Clinical and Laboratory Standards Institute; 2002.
102. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother. 2002;46:1773-1780.
103. Bachmann SP, Vande Walle K, Ramage G, et al. In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob Agents Chemother. 2002;46:3591-3596.